The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), and have a lower Charlson comorbidity score (2.6 vs 2.8) compared with those ...
The study also relied on the historical context provided by the University of Hawaiʻi at Mānoa Hawai‘i Ocean Time-series ...
Full-fat cheeses have been blamed as contributors for everything from obesity to heart disease, but surprising new research ...
In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Updated production data indicate that the Marcellus shale shows no evidence of declining resource quality or well ...
Researchers have discovered how cells activate a last-resort DNA repair system when severe damage strikes. When genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback